Cover Image
市場調查報告書

腦膜炎疫苗的全球市場:2016∼2020年

Global Meningococcal Vaccines Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 310811
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
腦膜炎疫苗的全球市場:2016∼2020年 Global Meningococcal Vaccines Market 2016-2020
出版日期: 2016年07月18日 內容資訊: 英文 68 Pages
簡介

腦膜炎特徵是腦和脊髓的保護粘膜(髓薄膜)發炎,分為感染性和非感染性。全球腦膜炎疫苗市場,以2016∼2020年以年複合成長率13.07%擴大。

本報告提供全球腦膜炎疫苗市場相關調查,市場成長預測,各地區趨勢,市場趨勢與課題,主要供應商的競爭趨勢等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 疫苗概要

  • 腦膜炎性疾病的理解
  • 腦膜炎性疾病的原因
  • 徵兆與症狀
  • 流行病學
  • 疫苗認證流程

第6章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 腦膜炎疫苗的全球市場:各組成市場分類

  • 單一疫苗
  • 並用疫苗

第8章 腦膜炎疫苗的全球市場:各地區分類

  • 各地區分類
  • 南北美洲
  • 美國
  • 巴西
  • 歐洲、中東、非洲
  • 歐洲
  • 亞太地區
  • 澳洲

第9章 腦膜炎疫苗的全球市場:促進要素

  • 疫苗接種計劃相關的認識高漲
  • 指定為旅客疫苗
  • 國家疫苗接種計劃的引進
  • 生物恐怖行動的威脅
  • 追加年齡族群的認證

第10章 促進要素的影響

第11章 腦膜炎疫苗的全球市場:課題

  • 疫苗的不足和處理上的問題
  • 疫苗開發伴隨的高成本
  • 嚴厲的法律規章
  • 本地企業的登場
  • 副作用

第12章 促進要素與課題的影響

第13章 腦膜炎疫苗的全球市場:趨勢

第14章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2015年
  • GlaxoSmithKline (GSK)
  • Pfizer
  • 其他值得注意的供應商

第15章 附錄

第16章 關於Technavio

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR9417

About Meningitis

Meningitis (meningococcal diseases) is characterized by inflammation of the protective lining (meninges) present around the brain and spinal cord. It can be classified into infectious and non-infectious meningitis. Based on the types of organism, infectious meningitis is sub-divided into bacterial meningitis, viral meningitis, fungal meningitis, and parasitic meningitis. Bacterial meningitis occurs due to bacterial species such as hemophilus influenzae, listeria monocytogenes, neisseria meningitidis, and streptococcus pneumoniae.

Technavio's analysts forecast the global meningococcal vaccines market to grow at a CAGR of 13.07% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global meningococcal vaccines market for 2016-2020. To calculate the market size, the report considers the the report considers the revenue generated from the sales of vaccines used to prevent meningococcal infections.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Meningococcal Vaccines Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • GSK
  • Pfizer
  • Sanofi

Other Prominent Vendors

  • Beijing Minhai Biotechnology
  • Bio Med
  • Hualan Biological Engineering
  • Imunoloski Zavod
  • JN International Medical
  • Nuron Biotech
  • Serum Institute of India
  • Vacunas Finlay SA
  • Merck
  • GlycoVaxyn
  • Baxter

Market driver

  • Designated as a traveller's vaccine
  • For a full, detailed list, view our report

Market challenge

  • High cost associated with vaccine development
  • For a full, detailed list, view our report

Market trend

  • Increase in strategic alliances and M&A
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Key buying criteria

PART 05: Overview of vaccines

  • Understanding Meningococcal disease
  • Causes of meningococcal diseases
  • Signs and symptoms
  • Epidemiology
  • Vaccine approval process

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Market segmentation by composition

  • Mono vaccines
  • Combination vaccines

PART 08: Geographical segmentation

  • Global meningococcal vaccines market by geographical segmentation 2015-2020
  • Meningococcal vaccines market in Americas
  • Meningococcal vaccines market in US
  • Meningococcal vaccines market in the Brazil
  • Meningococcal vaccines market in EMEA
  • Meningococcal vaccines market in Europe
  • Meningococcal vaccines market in APAC
  • Meningococcal vaccines market in Australia

PART 09: Market drivers

  • Increase in awareness about vaccination and immunization programs
  • Designated as a traveler's vaccine
  • Inclusion in national immunization schedule
  • Threat of bioterrorism
  • Additional age group approval

PART 10: Impact of drivers

PART 11: Market challenges

  • Vaccine storage and handling issues
  • High cost associated with vaccine development
  • Stringent regulations
  • Emergence of local players
  • Adverse effects

PART 12: Impact of drivers and challenges

PART 13: Market trends

  • Availability of combination vaccines
  • Increase in strategic alliances and M&A
  • Focus on emerging markets
  • Public-private initiatives

PART 14: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • Sanofi
  • GlaxoSmithKline (GSK)
  • Pfizer
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

PART 16: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key buying criteria for meningococcal vaccines
  • Exhibit 03: Distribution of meningococcal bacterial strains
  • Exhibit 04: Distribution of meningococcal bacterial strains in US
  • Exhibit 05: Distribution of meningococcal bacterial strains UK
  • Exhibit 06: Different type of bacterial causes of meningitis
  • Exhibit 07: Requirements for a BLA submission
  • Exhibit 08: Different types of development necessary to reach vaccine licensing stage
  • Exhibit 09: Vaccine development process over a period of up to 15 years at a cost of up to $1 billion
  • Exhibit 10: Regulatory testing of licensed vaccines
  • Exhibit 11: Pediatric/VFC meningococcal vaccine price list 2015
  • Exhibit 12: Price of adult meningococcal vaccine 2015
  • Exhibit 13: Global meningococcal vaccines market 2015-2020 ($ billions)
  • Exhibit 14: Five forces analysis
  • Exhibit 15: Global meningococcal vaccines market segmentation by composition
  • Exhibit 16: Global meningococcal vaccines market by composition 2015
  • Exhibit 17: Global meningococcal vaccines market by geography 2015
  • Exhibit 18: Global meningococcal vaccines market revenue by geography 2015-2020 ($ millions)
  • Exhibit 19: Percentage share of meningococcal vaccines market by geography 2015-2020
  • Exhibit 20: Global meningococcal vaccines market: YoY revenue and growth based on geography 2015-2020 ($ millions)
  • Exhibit 21: Meningococcal vaccines market in Americas 2015-2020 ($ billions)
  • Exhibit 22: Meningococcal vaccines market in America by country 2015
  • Exhibit 23: Meningococcal vaccines market in US 2015-2020 ($ billions)
  • Exhibit 24: Meningococcal vaccines market in Brazil 2015-2020 ($ millions)
  • Exhibit 25: Meningococcal vaccines market in EMEA 2015-2020 ($ millions)
  • Exhibit 26: Meningococcal vaccines market in EMEA by country 2015
  • Exhibit 27: Meningococcal vaccines market in Europe 2015-2020 ($ millions)
  • Exhibit 28: Meningococcal vaccines market in APAC 2015-2020 ($ millions)
  • Exhibit 29: Meningococcal vaccines market in APAC by country 2015
  • Exhibit 30: Meningococcal vaccines market in Australia 2015-2020 ($ millions)
  • Exhibit 31: Impact of drivers
  • Exhibit 32: A typical cold chain process
  • Exhibit 33: Impact of drivers and challenges
  • Exhibit 34: Overview of major vaccine related acquisitions (2005-2012)
  • Exhibit 35: Market share analysis of global meningococcal vaccines market 2015
  • Exhibit 36: Sanofi: YoY revenue growth of Meningitis/Pneumonia vaccines 2013-2015 ($ millions)
  • Exhibit 37: Geographical segmentation of meningitis/pneumococcal vaccines by revenue 2015
  • Exhibit 38: Sanofi: YoY revenue growth of Menactra 2013-2015 ($ millions)
  • Exhibit 39: Geographical segmentation of Menomune by revenue 2015
  • Exhibit 40: Key takeaways
  • Exhibit 41: Geographical segmentation of Bexsero by revenue 2015
  • Exhibit 42: Geographical segmentation of Menveo by revenue 2015
  • Exhibit 43: Key takeaways
  • Exhibit 44: Key takeaways
Back to Top